BLACK FRIDAY EARLY — BOGO 50% SITEWIDE

HGH Fragment 176-191 vs AOD-9604: Same Origin, Different Research Paths

By the Ageless Humans editorial team · Updated 2026-11-14 · 7 min read

HGH fragment 176-191 and AOD-9604 are nearly the same molecule. Both are short peptides copied from the tail end of human growth hormone, and AOD-9604 is a slightly modified version of that fragment with an extra tyrosine at one end. The real difference is their research history. Fragment 176-191 has been studied mostly in animals and cell models. AOD-9604 was developed as a drug candidate and went into human trials, but it never became an approved product.

The Short Answer: One Fragment, One Modification

AOD-9604 is a modified form of HGH fragment 176-191. Both peptides come from the same region of the human growth hormone (hGH) molecule, the last stretch of amino acids at the C-terminal end. AOD-9604 was engineered from that region with one key change: a tyrosine residue added to the N-terminus (the front end of the chain). That is why you will sometimes see it written as Tyr-hGH 177-191.

Functionally, researchers built AOD-9604 to be a more stable, drug-ready version of the fragment. The goal was to keep the part of growth hormone that research suggested was involved in fat metabolism and leave behind the parts tied to growth, IGF-1 signaling, and blood sugar.

So when people ask which one is "better," they are really asking a different question. These two are not rival compounds. They are close relatives, and the more useful comparison is how much each has been studied, in what settings, and what that research did and did not show.

Where Both Peptides Come From

Both peptides are pieces of growth hormone, not growth hormone itself. Full human growth hormone is a 191-amino-acid protein with many jobs, including tissue growth, regulating how the body uses fuel, and stimulating IGF-1 production in the liver. Those jobs map to different regions of the molecule.

In the 1990s, researchers in Australia, connected to Monash University, began looking at whether the C-terminal tail of hGH might carry some of the hormone's fat-metabolism activity on its own. The idea was simple. If you could isolate that piece, you might be able to study GH's metabolic effects without its growth-promoting effects.

That work produced the synthetic fragment covering amino acids 176 to 191, which became known as HGH fragment 176-191. The work later carried over into AOD-9604, where "AOD" is short for "anti-obesity drug," a name that reflects its original development goal and not any established outcome. For a deeper look at each compound on its own, see our guides to HGH fragment 176-191 benefits and research and AOD-9604 benefits and research.

Structural Overlap: Side by Side

The two peptides share almost the same amino acid sequence. Here is how they compare structurally:

  • Source region: Both come from the C-terminal end of human growth hormone.
  • Sequence: Fragment 176-191 matches hGH residues 176 through 191. AOD-9604 uses residues 177 through 191 with a tyrosine added at the N-terminus.
  • Length: Both are roughly 15 to 16 amino acids long. That is a small fraction of full GH's 191 residues.
  • Disulfide bridge: Both keep the cysteine-to-cysteine bond found in this region of GH. That bond helps hold the peptide's loop shape.
  • Design intent: Fragment 176-191 was an investigational tool. AOD-9604 was built as a drug candidate, and its modification was meant to improve stability.

Because the sequences overlap so much, early preclinical findings on one are often discussed alongside the other. That can be useful context. It can also blur the picture, because findings on one molecule do not automatically transfer to the other. Small structural changes can affect how a peptide holds up in the body and how it behaves in a study.

In practice, much online content treats them as interchangeable. A careful reader should not. Look for which exact compound a given study used.

Research State: HGH Fragment 176-191

Most research on HGH fragment 176-191 is preclinical, meaning animal and cell studies. Rodent work from the 1990s and early 2000s explored whether the fragment influenced fat metabolism. That included lipolysis, which is the breakdown of stored fat, and lipogenesis, which is the formation of new fat.

Those studies suggested the fragment might affect fat-cell metabolism in certain rodent models. They also suggested it did not seem to raise IGF-1 or affect blood sugar the way full growth hormone does. Some researchers looked at whether beta-3 adrenergic pathways were involved, though the mechanism was never fully settled.

What the research does not show is just as important:

  • There is no robust body of controlled human trials on fragment 176-191 itself.
  • Animal results, especially in rodents, often do not carry over to people.
  • Long-term safety data in humans is lacking.

The honest summary is that fragment 176-191 was an interesting early research tool. It helped scientists ask whether GH's metabolic effects could be separated from its growth effects. It is not a well-characterized human compound.

Research State: AOD-9604

AOD-9604 went further than the original fragment because it entered human clinical trials, but it did not become an approved drug. In the early-to-mid 2000s, it was studied in people as a possible weight-management treatment. Published reports from that period generally described it as well tolerated in the trial settings studied.

The larger trials, however, did not show enough benefit for developers to keep pursuing that use. Development for weight management was stopped. That is a key fact many marketing pages leave out. The compound's best-known intended use did not hold up in the larger human studies.

After that, researchers explored AOD-9604 in other areas, including preclinical work on cartilage and joint tissue in animal models. Those studies were early and limited, and they do not establish any effect in humans.

So AOD-9604 has more human data than fragment 176-191, and that data includes tolerability information. But the human data that exists did not confirm the outcome the compound was designed for. Anyone presenting AOD-9604 as a proven fat-loss agent is overstating the evidence.

Key Differences That Actually Matter

The meaningful differences come down to structure, research depth, and development history, not to which one "works better." Here is the practical breakdown:

1. Structure: AOD-9604 has an added N-terminal tyrosine. Fragment 176-191 is the unmodified hGH sequence. 2. Purpose: Fragment 176-191 was a research tool for studying how GH works. AOD-9604 was designed as a pharmaceutical candidate. 3. Human evidence: AOD-9604 has controlled human trial data. Fragment 176-191 largely does not. 4. Outcome of that evidence: AOD-9604's human trials did not support further development for its intended use. 5. What they have in common: Neither is an approved drug, and both lack long-term human safety data in the settings where they are often promoted.

One point often gets overlooked. More research does not mean better results. AOD-9604 is better studied, and the studies narrowed expectations instead of confirming them. Fragment 176-191 has fewer studies, so there is simply less data to evaluate.

If you see a product page claiming either peptide delivers specific results, ask three questions. Which compound was studied? Was the study in humans? Was the outcome in the study the same as the outcome being promised?

Regulatory and Anti-Doping Status

Neither HGH fragment 176-191 nor AOD-9604 is an FDA-approved drug or a legal dietary supplement ingredient. They are generally sold online as "research chemicals," often labeled "not for human consumption." That label is a legal disclaimer. It is not a quality standard. These products are not held to the manufacturing and testing requirements that apply to approved drugs or properly made supplements.

That creates real-world uncertainty. With unregulated peptides, buyers usually cannot confirm purity, concentration, sterility, or even whether the vial contains the stated compound. Regulators have scrutinized peptide compounding in recent years, and the rules around these substances have been changing.

For athletes, the answer is simple. The World Anti-Doping Agency (WADA) prohibited list names growth hormone fragments, specifically including AOD-9604 and hGH 176-191. Tested athletes should treat both as banned at all times.

Anyone considering any peptide should talk with a licensed healthcare provider first. This article is educational and is not a recommendation to use either compound.

A Grounded Approach to Metabolic Health

Evidence-supported foundations do more for metabolic health than unapproved peptides. The reason these fragments drew research interest at all is that metabolism, energy use, and body composition matter to healthy aging. Those goals are real. Much of the online peptide market, though, is ahead of the science.

The basics are well established: consistent resistance training, enough protein, good sleep, daily movement, and managing stress. Sleep in particular is closely tied to how the body regulates hunger, energy, and recovery overnight.

Some people also add well-made dietary supplements to their routine. Those formulas do not replicate peptide research, and they should not claim to. What separates a responsible supplement from a gray-market vial is accountability. You want to know where it was made, how it was tested, and what it actually contains.

That is why every Ageless Humans product is made in our FDA-registered facility in Carlsbad, California. Every lot is third-party lab tested with a Certificate of Analysis (COA), and every product is backed by a 60-day money-back guarantee.

Related reading & products

Frequently asked questions

Is AOD-9604 the same as HGH fragment 176-191?+

No, but they are very close. AOD-9604 is a modified version of HGH fragment 176-191, built from growth hormone residues 177 to 191 with a tyrosine added at the N-terminus. The change was meant to make the peptide more stable as a drug candidate. Research on one should not be assumed to apply to the other.

Which has more research, HGH fragment 176-191 or AOD-9604?+

AOD-9604 has more research, including controlled human clinical trials from the early-to-mid 2000s. HGH fragment 176-191 has been studied mostly in animal and cell models. AOD-9604's larger human trials did not show enough benefit for development as a weight-management drug to continue, so more research has not meant stronger results.

Do HGH fragment 176-191 or AOD-9604 raise IGF-1?+

Preclinical research suggested that these C-terminal growth hormone fragments did not raise IGF-1 the way full growth hormone does. Separating GH's metabolic activity from its growth-promoting activity was the main reason researchers studied them. Long-term human data on IGF-1 and safety remains limited.

Are HGH fragment 176-191 and AOD-9604 legal?+

Neither is an FDA-approved drug or a legal dietary supplement ingredient. Both are typically sold as "research chemicals" labeled not for human consumption, which means their quality, purity, and contents are not regulated. Rules around peptide compounding have also been changing, so anyone considering them should consult a licensed healthcare provider.

Are AOD-9604 and HGH fragment 176-191 banned in sports?+

Yes. The World Anti-Doping Agency's prohibited list names growth hormone fragments, specifically including AOD-9604 and hGH 176-191. Tested athletes should treat both as prohibited at all times, in and out of competition.

Why did AOD-9604 not become an approved drug?+

AOD-9604 was developed as a weight-management drug candidate and entered human clinical trials. The larger trials did not show enough benefit to justify further development for that use, so it was stopped. Researchers later looked at other areas, such as cartilage, in early animal studies, but no approved use resulted.

Keep reading